Replimune Group, Inc. (REPL) Stock Score, Valuation & Financial Research

Replimune Group, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for REPL

Replimune Group, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 11.39. These figures are a research snapshot, not a buy or sell recommendation.

What Replimune Group, Inc. does

Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.

Company business and revenue

Research reporting period: 2026-03-31. A research update is not a new financial filing.

How the company makes money

Replimune Group, Inc. is a clinical-stage biotechnology company that does not currently generate product revenue. Its business model focuses on the research and development of novel oncolytic immunotherapies to treat cancer, funded primarily through capital raises and equity financing while it advances its clinical pipeline toward potential commercialization.

Products and services

  • The company is developing a pipeline of oncolytic immunotherapy candidates, including RP1, RP2, and RP3, designed to selectively replicate in and kill tumor cells while inducing a systemic anti-tumor immune response.

Customer types

Clinical trial participants.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials and drug candidates. Source

Competitors and product-market comparisons

  • Amgen Inc. — Competes in the oncolytic virus therapy space with its product T-VEC (Imlygic). Source

Business strengths to evaluate

  • Proprietary Immulytic platform technology Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on the success of clinical-stage product candidates Source
  • Reliance on third-party manufacturers for clinical supply Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

REPL financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 11.39
Market capitalization:
1.07B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -297.01M
Free cash flow:
USD -284.57M
Cash:
USD 185.36M
Total debt:
USD 111.98M
EPS:
USD -3.15

What stands out

  • Free cash flow is USD -284.57M, negative for the stored period.
  • The balance sheet shows USD 185.36M of cash versus USD 111.98M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 73.38M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for REPL

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can REPL fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is REPL likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for REPL to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of REPL's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-15.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research REPL

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.